disulfiram has been researched along with Sepsis in 6 studies
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we assessed the role of CO donor, methylene chloride (MC), on modulation of lung inflammation during sepsis." | 7.76 | Methylene chloride protects against cecal ligation and puncture-induced acute lung injury by modulating inflammatory mediators. ( Dou, L; He, J; Pan, X; Pang, Q; Xu, W; Zeng, S; Zeng, Y, 2010) |
| " In this study, we assessed the role of CO donor, methylene chloride (MC), on modulation of lung inflammation during sepsis." | 3.76 | Methylene chloride protects against cecal ligation and puncture-induced acute lung injury by modulating inflammatory mediators. ( Dou, L; He, J; Pan, X; Pang, Q; Xu, W; Zeng, S; Zeng, Y, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 5 (83.33) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, C | 1 |
| Yue, H | 1 |
| Sun, P | 1 |
| Hua, L | 1 |
| Liang, S | 1 |
| Ou, Y | 1 |
| Wu, D | 1 |
| Wu, X | 1 |
| Chen, H | 1 |
| Hao, Y | 1 |
| Hu, W | 1 |
| Yang, Z | 1 |
| Klimiankou, M | 1 |
| Skokowa, J | 1 |
| Tan, C | 1 |
| Reilly, B | 1 |
| Jha, A | 1 |
| Murao, A | 1 |
| Lee, Y | 1 |
| Brenner, M | 1 |
| Aziz, M | 1 |
| Wang, P | 1 |
| Hu, JJ | 1 |
| Liu, X | 1 |
| Xia, S | 1 |
| Zhang, Z | 1 |
| Zhang, Y | 1 |
| Zhao, J | 1 |
| Ruan, J | 1 |
| Luo, X | 1 |
| Lou, X | 1 |
| Bai, Y | 1 |
| Wang, J | 1 |
| Hollingsworth, LR | 1 |
| Magupalli, VG | 1 |
| Zhao, L | 1 |
| Luo, HR | 1 |
| Kim, J | 1 |
| Lieberman, J | 1 |
| Wu, H | 1 |
| Silva, CMS | 1 |
| Wanderley, CWS | 1 |
| Veras, FP | 1 |
| Sonego, F | 1 |
| Nascimento, DC | 1 |
| Gonçalves, AV | 1 |
| Martins, TV | 1 |
| Cólon, DF | 1 |
| Borges, VF | 1 |
| Brauer, VS | 1 |
| Damasceno, LEA | 1 |
| Silva, KP | 1 |
| Toller-Kawahisa, JE | 1 |
| Batah, SS | 1 |
| Souza, ALJ | 1 |
| Monteiro, VS | 1 |
| Oliveira, AER | 1 |
| Donate, PB | 1 |
| Zoppi, D | 1 |
| Borges, MC | 1 |
| Almeida, F | 1 |
| Nakaya, HI | 1 |
| Fabro, AT | 1 |
| Cunha, TM | 1 |
| Alves-Filho, JC | 1 |
| Zamboni, DS | 1 |
| Cunha, FQ | 1 |
| Pang, Q | 1 |
| Dou, L | 1 |
| Pan, X | 1 |
| Zeng, S | 1 |
| He, J | 1 |
| Xu, W | 1 |
| Zeng, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| DISulfiram for COvid-19 (DISCO) Trial: A Phase 2 Double-Blind, Randomized Placebo-Controlled Trial of Disulfiram Compared to Standard Care in Patients With Symptomatic COVID-19[NCT04485130] | Phase 2 | 11 participants (Actual) | Interventional | 2021-08-18 | Terminated (stopped due to Low COVID case numbers, competing COVID treatments available) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The severity of COVID-19 symptoms will be recorded on a 5-point symptom severity scale at each visit for each participant. A question about how much the symptoms bother the participants will be asked. The participant will rank 1 as not at all, 2 as a little bit, 3 as somewhat, 4 as quite a bit and 5 as very much. Higher values represent worse outcomes. Scales are combined to compute a total score at Day 0 and Day 31. A change of the median is reported." (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | units on a scale (Median) |
|---|---|
| Cohort 1: Disulfiram | -2.60 |
| Cohort 1: Placebo | -2.14 |
Change in copies of SARS-CoV-2 PCR virus per mL between Baseline and Day 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | copies/mL (Mean) |
|---|---|
| Cohort 1: Disulfiram 1000 mg | -20.89 |
| Cohort 1: Placebo | -20 |
Change in plasma inflammatory biomarker levels (e.g., IL-6, IL-1b) at days 5, 15, and 31. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | fold change (Median) | |
|---|---|---|
| Change in IL-6 (pg/mL) Day 0 to 31 | Change in IL-1B (pg/mL) Day 0 to 31 | |
| Cohort 1: Disulfiram 100 mg | -0.1186 | -0.1402 |
| Cohort 1: Placebo | -0.0215 | 0.0268 |
The safety and tolerability of a 5 day course of disulfiram. The number of adverse events and their grade will be determined for each participant. (NCT04485130)
Timeframe: Day 0 and Day 31
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| AE Grade 3 or Higher | AE Grade 1 or 2 | |
| Cohort 1: Disulfiram 1000 mg | 0 | 4 |
| Cohort 1: Placebo | 1 | 1 |
6 other studies available for disulfiram and Sepsis
| Article | Year |
|---|---|
Discovery of chalcone analogues as novel NLRP3 inflammasome inhibitors with potent anti-inflammation activities.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Chalcones; Colitis; Disease Models, Animal; Drug Desig | 2021 |
Old drug revisited: disulfiram, NETs, and sepsis.
Topics: Disulfiram; Extracellular Traps; Humans; Pharmaceutical Preparations; Sepsis | 2021 |
Active Release of eCIRP via Gasdermin D Channels to Induce Inflammation in Sepsis.
Topics: Animals; Disulfiram; Inflammation; Intracellular Signaling Peptides and Proteins; Lipopolysaccharide | 2022 |
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation.
Topics: Animals; Caspase 1; Caspase Inhibitors; Caspases; Caspases, Initiator; Cell Line, Tumor; Disulfiram; | 2020 |
Gasdermin D inhibition prevents multiple organ dysfunction during sepsis by blocking NET formation.
Topics: Acetaldehyde Dehydrogenase Inhibitors; Adoptive Transfer; Aged; Animals; Cells, Cultured; Disulfiram | 2021 |
Methylene chloride protects against cecal ligation and puncture-induced acute lung injury by modulating inflammatory mediators.
Topics: Acute Lung Injury; Animals; Carbon Monoxide; Cecum; Cytoprotection; Disease Models, Animal; Disulfir | 2010 |